Vecuronium BromideNonpolarizing neuromuscular relaxant CAS# 50700-72-6 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rocuronium Bromide
Catalog No.:BCC1068
CAS No.:119302-91-9
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 50700-72-6 | SDF | Download SDF |
| PubChem ID | 39764 | Appearance | Powder |
| Formula | C34H57BrN2O4 | M.Wt | 637.73 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 46 mg/mL (72.13 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;bromide | ||
| SMILES | CC(=O)OC1CC2CCC3C(C2(CC1N4CCCCC4)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-] | ||
| Standard InChIKey | VEPSYABRBFXYIB-PWXDFCLTSA-M | ||
| Standard InChI | InChI=1S/C34H57N2O4.BrH/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36;/h25-32H,6-22H2,1-5H3;1H/q+1;/p-1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Vecuronium (bromide) is a muscle relaxant in the category of non-depolarizing blocking agents.
Target: nAChR
Vecuronium (Norcuron) is a muscle relaxant in the category of non-depolarizing blocking agents. Vecuronium bromide is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. In adolescents the vecuronium requirement was less than in children and was comparable to that reported in adults in other studies (89 +/- 13 micrograms.kg-1.hr-1) [1]. Infusions of Vecuronium provided much smoother control of neuromuscular blockade than did pancuronium. No cardiovascular side-effects were noted even at the greatest dose (0.12 mg kg-1) used. Vecuronium has clear advantages over pancuronium and represents a potentially valuable addition to the armamentarium of clinically useful muscle relaxants [2]. The onset times of the 0.6 and 0.9 mg x kg(-1) of Org 9426 groups were 84.6 and 77.1 sec respectively, which showed statistical difference between the onset time of 0.1 mg x kg(-1) of vecuronium, 125.7 sec. The intubation condition was similar among three treatment groups. The clinical durations of 0.6 and 0.9 mg x kg(-1) of Org 9426 and 0.1 mg x kg(-1) of vecuronium were 53.4, 73.4 and 59.9 min, respectively. Clinical duration and spontaneous recovery time of maintenance dose of 0.15 mg x kg(-1) of Org 9426 were similar to those of 0.025 mg x kg(-1) of vecuronium [3].
Clinical indications: Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia. References: | |||||
Vecuronium Bromide Dilution Calculator
Vecuronium Bromide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5681 mL | 7.8403 mL | 15.6806 mL | 31.3612 mL | 39.2015 mL |
| 5 mM | 0.3136 mL | 1.5681 mL | 3.1361 mL | 6.2722 mL | 7.8403 mL |
| 10 mM | 0.1568 mL | 0.784 mL | 1.5681 mL | 3.1361 mL | 3.9202 mL |
| 50 mM | 0.0314 mL | 0.1568 mL | 0.3136 mL | 0.6272 mL | 0.784 mL |
| 100 mM | 0.0157 mL | 0.0784 mL | 0.1568 mL | 0.3136 mL | 0.392 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Vecuronium Bromide is a nonpolarizing neuromuscular relaxant.
- Pennogenin
Catalog No.:BCN2839
CAS No.:507-89-1
- Borneol
Catalog No.:BCN4964
CAS No.:507-70-0
- Boc-Cys(Bzl)-OH
Catalog No.:BCC3376
CAS No.:5068-28-0
- Terfenadine
Catalog No.:BCC3866
CAS No.:50679-08-8
- Chasmanine
Catalog No.:BCN5409
CAS No.:5066-78-4
- Vandrikidine
Catalog No.:BCN5615
CAS No.:50656-92-3
- Alkaloid C
Catalog No.:BCN1897
CAS No.:50656-88-7
- Alkaloid KD1
Catalog No.:BCN1898
CAS No.:50656-87-6
- Niranthin
Catalog No.:BCN5614
CAS No.:50656-77-4
- Octacosanoic Acid
Catalog No.:BCN5395
CAS No.:506-48-9
- Nervonic acid
Catalog No.:BCN8374
CAS No.:506-37-6
- Arachidonic acid
Catalog No.:BCN2215
CAS No.:506-32-1
- 3-Cyano-6-isopropylchromone
Catalog No.:BCC8627
CAS No.:50743-32-3
- TPCA-1
Catalog No.:BCC2473
CAS No.:507475-17-4
- Polyphyllin D
Catalog No.:BCN2401
CAS No.:50773-41-6
- Polyphyllin B
Catalog No.:BCN2833
CAS No.:50773-42-7
- Soyasapogenol A
Catalog No.:BCN1433
CAS No.:508-01-0
- Oleanolic acid
Catalog No.:BCN5616
CAS No.:508-02-1
- 13(18)-Oleanen-3-ol
Catalog No.:BCN5617
CAS No.:508-04-3
- Glutinone
Catalog No.:BCN5618
CAS No.:508-09-8
- N-acetylanonaine
Catalog No.:BCN2666
CAS No.:5894-74-6
- Ouabagenin
Catalog No.:BCC8227
CAS No.:508-52-1
- Rosenonolactone
Catalog No.:BCN5621
CAS No.:508-71-4
- Convallatoxin
Catalog No.:BCC8155
CAS No.:508-75-8
Biophysical study on the interaction of an anesthetic, vecuronium bromide with human serum albumin using spectroscopic and calorimetric methods.[Pubmed:25255425]
J Photochem Photobiol B. 2014 Nov;140:381-9.
The interactions between an anesthetic, Vecuronium Bromide (VB) and human serum albumin (HSA) have been investigated systematically by steady-state/time-resolved fluorescence, circular dichroism (CD), UV-vis absorption, Fourier transform infrared spectroscopy (FTIR), mass spectroscopy and differential scanning calorimetry (DSC) methods under physiological conditions. The fluorescence quenching observed is attributed to the formation of a complex between HSA and VB, and the reverse temperature effect of the fluorescence quenching has been found and discussed. Fluorescence analysis has proved that there is one classical binding site on HSA for VB with a relative weak binding constant of 1.07 x 10(4)M(-1) at 298 K. The primary binding pattern is determined by hydrogen bonding or van der Waals forces occurring in site I of HSA with DeltaG degrees =-2.30 x 10(4)J mol(-1), DeltaS degrees =-233 J mol(-1)K(-1) and DeltaH degrees =-9.23 x 10(4)J mol(-1) at 298 K. VB could slightly change the secondary structure and induce unfolding of the polypeptides of protein. The DSC results provide quantitative information on the effect of VB on the stability of serum albumin. It is shown that VB can efficiently bind with HSA and be transported to the focuses needed.
Intraoperative hemodynamics with vecuronium bromide and rocuronium for maintenance under general anesthesia.[Pubmed:26957692]
Anesth Essays Res. 2016 Jan-Apr;10(1):59-64.
AIMS: The present study is undertaken to compare the hemodynamic effects using vecuronium versus rocuronium for maintenance in patients undergoing general surgical procedures. SETTINGS AND DESIGN: It is a prospective, randomized, and cohort study. SUBJECTS AND METHODS: 100 patients were randomly divided into two groups. All patients were induced with 5 mg/kg of thiopentone sodium, and intubation conditions were achieved with 1.5 mg/kg of suxamethonium, using a well-lubricated cuffed endotracheal tube of appropriate size. When the patient started to breathe spontaneously, they were administered either 0.6 mg/kg of rocuronium (Group A) or 0.1 mg/kg of vecuronium (Group B). Hemodynamic parameters (heart rate and mean arterial pressure [MAP]) were monitored before administering the drug; at 1, 5, 10, 15, and 20 min after the drug and at the end of the surgery. STATISTICAL ANALYSIS USED: Data were compiled, analyzed and presented as frequency, proportions, mean, standard deviation, percentages, and t-test using SPSS (version 16). A P < 0.05 was considered as significant. RESULTS: The heart rate increased significantly at 1-min and 5-min after administration of rocuronium (83.76 +/- 10.37 and 86.8 +/- 9.98), unlike vecuronium. However, it gradually declined towards normal, and change in heart rate with either drug was not significant beyond 10 min. The MAP decreased significantly at 1-min after administration of rocuronium (96.68 +/- 7.57) which later showed a gradual increasing trend when compared to vecuronium which had no statistically significant change at any time. CONCLUSIONS: For short surgical procedures rocuronium is a good alternative to vecuronium, as the drug is reasonably cardio stable, produces excellent intubation conditions, has a shorter duration of action, and shows minimal cumulative effect.
Effects of intraoperative magnetic resonance imaging on the neuromuscular blockade of vecuronium bromide in neurosurgery.[Pubmed:23615407]
Neurol Med Chir (Tokyo). 2013;53(4):201-6.
The effects of intraoperative magnetic resonance (iMR) imaging on the neuromuscular blockade of Vecuronium Bromide were investigated in neurosurgery. Fifty patients with American Society of Anesthesiologists grades I-II scheduled for craniotomy operation were divided into two groups (n = 25 each) with no difference in demographic data: the iMR imaging group and control group. Train-of-four (TOF) stimulation through an accelerometer was used to monitor onset, maintenance, and recovery of muscle relaxation caused by vecuronium. Vecuronium Bromide was intravenously injected after anesthesia induction. The dosage of Vecuronium Bromide in the iMR imaging group was larger than in the control group, but not significantly. Duration of Vecuronium Bromide administration and operation time were significantly longer in the iMR imaging group than in the control group. Time from drug discontinuation to operation termination, and to return to neurosurgery intensive care unit were not different. Time taken by first twitch (T1) in response to TOF stimulation to recover by 25%, and muscle relaxant recovery index were significantly greater in the control group than in the iMR imaging group. The body temperature of the patients increased gradually in the iMR imaging group but decreased in the control group. iMR imaging can prolong the operation time, increase the body temperature of the patient, and remarkably shorten the clinical action time and muscle relaxation recovery index of vecuronium.
Comparison of intubating conditions of rocuronium bromide and vecuronium bromide with succinylcholine using "timing principle".[Pubmed:21547177]
J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):493-7.
BACKGROUND: Rapid and safe endotracheal intubation is of paramount importance in general anaesthesia. The aim of this study was to compare the intubating conditions of succinylcholine with rocuronium bromide and Vecuronium Bromide using "Timing principle". The timing principle entails administration of a single bolus dose of nondepolarizing muscle relaxant, followed by an induction drug at the onset of clinical weakness. PATIENTS #ENTITYSTARTX00026; METHODS: 75 patients were divided into three groups of 25 each. Patients allocated to Groups A and B received rocuronium 0.6 mg kg(-1) and vecuronium 0.12 mg kg(-1) respectively. At the onset of clinical weakness (ptosis), anesthesia was induced with propofol 2.5 mg kg(-1); intubation was accomplished after 60 seconds of induction agent in both groups. Patients in Group C received propofol 2.5mg kg(-1) followed by succinylcholine 2mg kg(-1) and their tracheas were intubated at 60s.Train of four count was assessed at adductor pollicis muscle using nerve stimulator at intubation and time to loss of TOF was observed. in group A and B. Intubating conditions were assessed according to a grading scale and haemodynamic variables were compared at 1,3 and 5 minutes after intubation. RESULTS: Intubating conditions were either excellent(84% in group A,48% in group B and 88% in group C) or good (16% in group A, 48% in group B and 12 %in group C)and only 4% pt had poor intubating conditions in group B. Patients were interviewed postoperatively, and all were satisfied with the technique of induction of anesthesia.Rocuronium and Vecuronium are haemodynamically stable drugs as compared to Succinylcholine. CONCLUSION: Rocuronium 0.6 mg kg(-1) provides good to excellent intubating conditions at 60 s comparable to succinylcholine after the induction of anesthesia using the timing principle.
